-
Je něco špatně v tomto záznamu ?
Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course
F. Delehaye, J. Rouger, D. Brossier, M. Suttorp, AM. Güneş, P. Sedlacek, B. Versluys, CK. Li, K. Kalwak, B. Lausen, C. Srdjana, M. Dworzak, A. Hraskova, B. De Moerloose, F. Roula, A. Briant, JJ. Parienti, F. Millot
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články
NLK
ProQuest Central
od 1997-03-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2000-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest)
od 1997-03-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1997-03-01 do Před 1 rokem
- MeSH
- anemie * farmakoterapie MeSH
- antitumorózní látky * terapeutické užití MeSH
- chronická myeloidní leukemie * farmakoterapie MeSH
- dítě MeSH
- dospělí MeSH
- hemoglobiny MeSH
- imatinib mesylát terapeutické užití MeSH
- inhibitory proteinkinas terapeutické užití MeSH
- lidé MeSH
- mladiství MeSH
- prevalence MeSH
- prognóza MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- Publikační typ
- časopisecké články MeSH
The clinical presentation of chronic myeloid leukemia (CML) at diagnosis differs in children compared to adults. At younger age, anemia appears to be frequent at diagnosis, but its prevalence and its impact on prognosis are not well known. In the International Registry of Childhood CML, we selected children and adolescents in chronic phase at diagnosis of CML and treated upfront with imatinib. We examined their hemoglobin level at diagnosis according to the WHO grades to assess the prevalence of anemia and its impact on response to tyrosine kinase inhibitors (TKIs). Data on 430 patients were included. Anemia at diagnosis was observed in 350 patients (81%), with a mean hemoglobin level of 96.4 g/l (SD 23.6). Among them, 182 patients (52%) presented with moderate anemia and 110 (31%) with severe anemia while 58 (17%) had mild anemia. Compared with mild and no anemia, moderate and severe forms were significantly associated with younger age at diagnosis, asthenia, splenomegaly, and increased leukocyte and basophil counts. Delays in achieving major and deep molecular responses were significantly increased for patients with moderate and severe anemia, and also failure of imatinib treatment was more frequent in these two sub-cohorts. However, hemoglobin level was not significantly associated with survival. Anemia at diagnosis of pediatric CML was frequent and may be considered as a prognostic factor.
Department of Biostatistics and Clinical Research University Hospital of Caen Normandy Caen France
Department of Pediatric Hematology Oncology Immunology and Medical Genetic Split Croatia
Department of Pediatric Hematology Uludağ University Hospital Görükle Bursa Turkey
Department of Pediatric Oncology of University Children's Hospital Bratislava Slovakia
Department of Pediatrics Ghent University Hospital Ghent Belgium
Department of Pediatrics Rigshospitalet University Hospital Copenhagen Denmark
Department of Pediatrics Saint George Hospital University Medical Centre Beirut Lebanon
Inserm University Hospital CIC 1402 Poitiers France
Pediatric Hemato Oncology Medical Faculty Technical University of Dresden Dresden Germany
Pediatric Intensive Care Unit CHU de Caen 14000 Caen France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004043
- 003
- CZ-PrNML
- 005
- 20230425141045.0
- 007
- ta
- 008
- 230418s2023 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00277-022-05024-1 $2 doi
- 035 __
- $a (PubMed)36370190
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Delehaye, Fanny $u Department of Pediatric Oncology and Hematology, University Hospital of Caen, Avenue de La Côte de Nacre, 14000, Caen, France. f.delehaye@gmail.com $1 https://orcid.org/000000022431398X
- 245 10
- $a Prevalence of anemia at diagnosis of pediatric chronic myeloid leukemia and prognostic impact on the disease course / $c F. Delehaye, J. Rouger, D. Brossier, M. Suttorp, AM. Güneş, P. Sedlacek, B. Versluys, CK. Li, K. Kalwak, B. Lausen, C. Srdjana, M. Dworzak, A. Hraskova, B. De Moerloose, F. Roula, A. Briant, JJ. Parienti, F. Millot
- 520 9_
- $a The clinical presentation of chronic myeloid leukemia (CML) at diagnosis differs in children compared to adults. At younger age, anemia appears to be frequent at diagnosis, but its prevalence and its impact on prognosis are not well known. In the International Registry of Childhood CML, we selected children and adolescents in chronic phase at diagnosis of CML and treated upfront with imatinib. We examined their hemoglobin level at diagnosis according to the WHO grades to assess the prevalence of anemia and its impact on response to tyrosine kinase inhibitors (TKIs). Data on 430 patients were included. Anemia at diagnosis was observed in 350 patients (81%), with a mean hemoglobin level of 96.4 g/l (SD 23.6). Among them, 182 patients (52%) presented with moderate anemia and 110 (31%) with severe anemia while 58 (17%) had mild anemia. Compared with mild and no anemia, moderate and severe forms were significantly associated with younger age at diagnosis, asthenia, splenomegaly, and increased leukocyte and basophil counts. Delays in achieving major and deep molecular responses were significantly increased for patients with moderate and severe anemia, and also failure of imatinib treatment was more frequent in these two sub-cohorts. However, hemoglobin level was not significantly associated with survival. Anemia at diagnosis of pediatric CML was frequent and may be considered as a prognostic factor.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a imatinib mesylát $x terapeutické užití $7 D000068877
- 650 _2
- $a prognóza $7 D011379
- 650 _2
- $a prevalence $7 D015995
- 650 12
- $a chronická myeloidní leukemie $x farmakoterapie $7 D015464
- 650 12
- $a anemie $x farmakoterapie $7 D000740
- 650 _2
- $a hemoglobiny $7 D006454
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 12
- $a antitumorózní látky $x terapeutické užití $7 D000970
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Rouger, Jérémie $u Department of Pediatric Oncology and Hematology, University Hospital of Caen, Avenue de La Côte de Nacre, 14000, Caen, France
- 700 1_
- $a Brossier, David $u Pediatric Intensive Care Unit, CHU de Caen, 14000, Caen, France $u Université Caen Normandie Medical School, 14000, Caen, France
- 700 1_
- $a Suttorp, Meinolf $u Pediatric Hemato-Oncology Medical Faculty, Technical University of Dresden, Dresden, Germany
- 700 1_
- $a Güneş, Adalet Meral $u Department of Pediatric Hematology, Uludağ University Hospital, Görükle, Bursa, Turkey
- 700 1_
- $a Sedlacek, Petr $u Department of Pediatric Hematology-Oncology, University Hospital Motole, Charles University, Prague, Czech Republic
- 700 1_
- $a Versluys, Birgitta $u Department of Pediatric Blood and Marrow Transplantation, Prinses Maxima Center, Utrecht, The Netherlands
- 700 1_
- $a Li, Chi Kong $u Department of Pediatrics, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China
- 700 1_
- $a Kalwak, Krzysztof $u Department of Pediatric Hematology Oncology and Transplantation, Wroclaw Medical University, Wroclaw, Poland
- 700 1_
- $a Lausen, Birgitte $u Department of Pediatrics, Rigshospitalet University Hospital, Copenhagen, Denmark
- 700 1_
- $a Srdjana, Culic $u Department of Pediatric Hematology, Oncology Immunology, and Medical Genetic, Split, Croatia
- 700 1_
- $a Dworzak, Michael $u St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria $u St. Anna Children's Hospital Medical University of Vienna Department of Pediatrics and Adolescent Medicine, Vienna, Austria
- 700 1_
- $a Hraskova, Andrea $u Department of Pediatric Oncology of University Children's Hospital, Bratislava, Slovakia
- 700 1_
- $a De Moerloose, Barbara $u Department of Pediatrics, Ghent University Hospital, Ghent, Belgium
- 700 1_
- $a Roula, Farah $u Department of Pediatrics, Saint George Hospital, University Medical Centre, Beirut, Lebanon
- 700 1_
- $a Briant, Anaïs $u Department of Biostatistics and Clinical Research, University Hospital of Caen, Normandy, Caen, France
- 700 1_
- $a Parienti, Jean-Jacques $u Department of Biostatistics and Clinical Research, University Hospital of Caen, Normandy, Caen, France
- 700 1_
- $a Millot, Frédéric $u Inserm, University Hospital, CIC 1402, Poitiers, France
- 773 0_
- $w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 102, č. 3 (2023), s. 563-570
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36370190 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141041 $b ABA008
- 999 __
- $a ok $b bmc $g 1924605 $s 1190252
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 102 $c 3 $d 563-570 $e 20221112 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
- LZP __
- $a Pubmed-20230418
